Stoke Therapeutics
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundament...
Latest News
18 days ago · seekingalpha.com
Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call TranscriptStoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript
18 days ago · marketbeat.com
Stoke Therapeutics Q3 Earnings Call HighlightsStoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR trial of zorevunersen in Dravet syndrome is advancing toward a planned third-quarter 2027 data readout, while the company prepares for a potential U.S. regulatory submission later that year and a possible launch in early 2028.
18 days ago · zacks.com
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue EstimatesStoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.65 per share a year ago.
28 days ago · seekingalpha.com
Stoke Therapeutics: The Market Misread A Key FDA WinStoke Therapeutics is positioned for a pivotal 2027 readout of zorevunersen, potentially the first disease-modifying Dravet syndrome therapy. STOK's cash runway extends to early 2028, supported by $420M in cash and a recent $65.7M share sale at a premium to market. The FDA's acceptance of a cognition/behavior endpoint for EMPEROR reduces regulatory risk and differentiates zorevunersen from symptomatic competitors.
1 month ago · businesswire.com
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet SyndromeBEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of a successful meeting with the U.S. Food and Drug Administration (FDA) intended to align on key aspects of the.
2 months ago · businesswire.com
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and CommercializationBEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Bo Cumbo to its Board of Directors. Concurrent with Mr. Cumbo's appointment, Edward Kaye, M.D., has retired.
2 months ago · gurufocus.com
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t[url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with
3 months ago · benzinga.com
These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 ResultsStoke Therapeutics Inc (NASDAQ:STOK) on Monday posted mixed results for the second quarter.
3 months ago · seekingalpha.com
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call TranscriptStoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript
4 months ago · zacks.com
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue EstimatesStoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.4 per share a year ago.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove STOK